QRXPharma just saw its market cap shrink 75% from $120mil to $30mil on the FDA saying 'no', as Matthijs smith warned Livewire yesterday: There is unlikely to...

QRXPharma just saw its market cap shrink 75% from $120mil to $30mil on the FDA saying 'no', as Matthijs smith warned Livewire yesterday: There is unlikely to be any pain relief for QRX investors tomorrow as the company heads into what looks to be a challenging session...Whatever happens, overnight, it is not going to be pretty. This morning QRX reported: United States Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee has voted to recommend against approval of Moxduo, an immediate release Dual Opioid® for the treatment of moderate to severe acute pain. The Advisory Committee found the Company did not provide sufficient evidence to warrant approval of Moxduo at this time. A terrible day for the company's investors.


The Livewire Equities feed brings you a range of insights that relate to Australian equities

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.